A REVIEW OF LIBMELDY

The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now accepted for all 5 indications across numerous hematological cancers.One explanation why the worth tag is so large will be to protect the costs of creating and developing the drug. The cost compensated through the NHS for this one-off procedure has to be established against the price o